Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/81554
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorYe, J-
dc.creatorChu, AJ-
dc.creatorLin, L-
dc.creatorYang, X-
dc.creatorMa, C-
dc.date.accessioned2019-10-28T05:46:02Z-
dc.date.available2019-10-28T05:46:02Z-
dc.identifier.issn1420-3049-
dc.identifier.urihttp://hdl.handle.net/10397/81554-
dc.language.isoenen_US
dc.publisherMolecular Diversity Preservation International (MDPI)en_US
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.rightsThe following publication Ye J, Chu AJ, Lin L, Yang X, Ma C. First-In-Class Inhibitors Targeting the Interaction between Bacterial RNA Polymerase and Sigma Initiation Factor Affect the Viability and Toxin Release of Streptococcus pneumoniae. Molecules. 2019; 24(16):2902, is available at https://doi.org/10.3390/molecules24162902en_US
dc.subjectAntimicrobial discoveryen_US
dc.subjectInhibitoren_US
dc.subjectRNA polymeraseen_US
dc.subjectSigma factoren_US
dc.subjectTranscriptionen_US
dc.titleFirst-in-class inhibitors targeting the interaction between bacterial RNA polymerase and sigma initiation factor affect the viability and toxin release of streptococcus pneumoniaeen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume24-
dc.identifier.issue16-
dc.identifier.doi10.3390/molecules24162902-
dcterms.abstractNovel antimicrobial classes are in desperate need for clinical management of infections caused by increasingly prevalent multi-drug resistant pathogens. The protein-protein interaction between bacterial RNA polymerase (RNAP) and the housekeeping sigma initiation factor is essential to transcription and bacterial viability. It also presents a potential target for antimicrobial discovery, for which a hit compound (C3) was previously identified from a pharmacophore modelbased in silico screen. In this study, the hit compound was experimentally assessed with some rationally designed derivatives for the antimicrobial activities, in particular against Streptococcus pneumoniae and other pathogens. One compound, C3-005, shows dramatically improved activity against pneumococci compared to C3. C3-005 also attenuates S. pneumoniae toxin production more strongly than existing classes of antibiotics tested. Here we demonstrate a newly validated antimicrobial agent to address an overlooked target in the hit-to-lead process, which may pave the way for further antimicrobial development.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationMolecules, 2 Aug. 2019, v. 24, no. 16, 2902-
dcterms.isPartOfMolecules-
dcterms.issued2019-08-02-
dc.identifier.scopus2-s2.0-85070681194-
dc.identifier.artn2902-
dc.description.validate201910 bcma-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumbera0734-n03, OA_Scopus/WOSen_US
dc.identifier.SubFormID1302-
dc.description.fundingSourceRGC-
dc.description.fundingSourceOthers-
dc.description.fundingTextRGC: 25100017-
dc.description.fundingTextOthers: P0000161-
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Ye_First-in-class_inhibitors_targeting.pdf1.25 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

259
Last Week
1
Last month
Citations as of Mar 24, 2024

Downloads

94
Citations as of Mar 24, 2024

SCOPUSTM   
Citations

12
Citations as of Mar 28, 2024

WEB OF SCIENCETM
Citations

12
Citations as of Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.